Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis
| Autor: | Pascal Delépine, Sylvie Attucci, Laurent Vecellio, C Valat, Patrice Diot, A Poncin, Francis Gauthier, Daniel Grimbert, F Saudubray, P Antonioz, E Boissinot |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Pulmonary and Respiratory Medicine
Cystic Fibrosis Serum albumin Administration Inhalation medicine Humans Pharmacology (medical) Particle Size Aerosolization Serpins Aerosols Chromatography Inhalation biology Chemistry Nebulizers and Vaporizers Elastase Proteins Equipment Design Human serum albumin Aerosol Elastase inhibitor Biochemistry Enzyme inhibitor biology.protein Linear Models medicine.drug |
| Zdroj: | Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine. 16(2) |
| ISSN: | 0894-2684 |
| Popis: | The purpose of this study was to define nebulization conditions providing delivery of aerosols of EPI-hNE4, an inhibitor of human neutrophil elastase (HNE). EPI-hNE4 was nebulized with Pari LC Star and tested at three concentrations (2.5, 5, and 10 mg/mL). The inhaled mass was measured over 15 min. Particle size distribution was measured by cascade impaction. The effect was also tested of mixing EPI-hNE4 with a (99m)Tc human serum albumin (HSA) tracer on the aerodynamic properties of the aerosol. The inhibitory activity of EPI-hNE4 after nebulization was assessed on purified HNE. The inhaled mass was 32.3 +/- 3.5% (mean +/- SD) after 10 min and 44.2 +/- 3.8% (mean +/- SD) after 15 min. Mass median aerodynamic diameter ranged between 1.2 and 1.8 microm. The (99m)Tc HSA EPI-hNE4 aerosol was similar in terms of particle size distribution (y = 1.0338x - 0.003, r = 0.83). (99m)Tc activity was predictive of EPI-hNE4 mass distribution (y = 1.0278x - 1.6991, r = 0.89). The inhibitory capacity of aerosolized samples remained unchanged after up to 10 min of nebulization. EPI-hNE4 can be nebulized efficiently without decrease in its activity. Mixing this inhibitor with (99m)Tc HSA should allow quantification of its deposition in CF patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|